US Pharma MarketingSeniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout HHS Politics research Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Novartis doubles down on molecular glue strategy Seniors’ drug costs rise sharply, Enliven’s leukemia drugs, and more biotech…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Medicare drug spending is climbing faster than expected, driven by surging use of GLP-1 medicines and ongoing fallout from Democrats’ Part D redesign.
Also, Enliven’s leukemia drug has encouraging early data, Novartis is expanding its molecular glue ambitions, and SonoThera raised $125 million to advance an ultrasound-based approach to gene delivery.
Source: STAT News Pharma